Alongside its approval as a test for understanding the genetic basis of a particular cancer, and linking oncologists with relevant clinical trial information, the FDA also granted the test the ability ...
Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...
While the advancement of comprehensive genomic profiling (CGP) ushers in a more targeted approach to treating patients with cancer, BillionToOne says its approach could overcome limitations present in ...
A lung cancer diagnosis is often described through familiar terms such as the stage, size and location of a tumour. But there is another layer of information that can be equally important when doctors ...
--Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy-- CAMBRIDGE, ...
Characterization of Non–Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns Among 31,165 (97.2%) samples where ...
The 31-gene expression profile test appears to allow for significant and independent risk stratification of those with stage I cutaneous melanoma. The 31-gene expression profile test, ...
The liquid biopsy test was also approved as a companion diagnostic test to uncover EGFR mutations in patients with NSCLC who could benefit from treatment with Tagrisso. The Food and Drug ...
Oncotarget published "Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®" which reported that the authors developed and analytically validated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results